Therapeutic Approach: The Importance of Controlling Prostatic Inflammation

Bostanci, 2013, Correlation between benign prostatic hyperplasia and inflammation, Curr Opin Urol, 23, 5, 10.1097/MOU.0b013e32835abd4a

Paubert-Braquet, 1997, Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils, Prostaglandins Leukot Essent Fatty Acids, 57, 299, 10.1016/S0952-3278(97)90548-2

Hussain, 2003, Cyclooxygenase-2 and prostate carcinogenesis, Cancer Lett, 191, 125, 10.1016/S0304-3835(02)00524-4

Tsujii, 1995, Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2, Cell, 83, 493, 10.1016/0092-8674(95)90127-2

Di Silverio, 2005, Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), Eur Urol, 47, 72, 10.1016/j.eururo.2004.08.024

Ozdemir, 2009, Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms, Urology, 74, 431, 10.1016/j.urology.2009.01.088

Fibbi, 2010, Chronic inflammation in the pathogenesis of benign prostatic hyperplasia, Int J Androl, 33, 475, 10.1111/j.1365-2605.2009.00972.x

Crescioli, 2004, Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia, Eur J Endocrinol, 150, 591, 10.1530/eje.0.1500591

Adorini, 2010, Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia, Ann N Y Acad Sci, 1193, 146, 10.1111/j.1749-6632.2009.05299.x

Penna, 2009, The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappa B pathways, Prostate, 69, 480, 10.1002/pros.20896

Ragab, 1998, Effects of Permixon (Sereprostat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells, 293

Sirab, 2013, Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells, Int J Mol Sci, 14, 14301, 10.3390/ijms140714301

Vela Navarrete, 2003, BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay, Eur Urol, 44, 549, 10.1016/S0302-2838(03)00368-3

Exploratory study of L.S.E.S.r. (lipidosterolic extract of Serenoa Repens) (PERMIXON® 160mg hard capsule) versus tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH (benign prostatic hyperplasia) (PERMIN). NCT01604811. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01604811?term=serenoa+repens&rank=4.

Latil, 2012, Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro, BJU Int, 110, E301, 10.1111/j.1464-410X.2012.11144.x

Bushman, 2009, Etiology, epidemiology, and natural history of benign prostatic hyperplasia, Urol Clin North Am, 36, 403, 10.1016/j.ucl.2009.07.003